Chardan Capital Markets resumed coverage on MeiraGTx with a new price target

7/31/24 6:30:53 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Chardan Capital Markets resumed coverage of MeiraGTx with a rating of Buy and set a new price target of $36.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MGTX

Date	Price Target	Rating	Analyst
7/31/2024	$36.00	Buy	Chardan Capital Markets